Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~For inclusion in the study subjects should fulfill the following criteria:~* Provision of informed consent prior to any study specific procedures~* Males and females aged 19 years and older~* Congruent to the PLATO trial, at least two of the following three criteria have to be met:~* ST-segment changes on electrocardiography, indicating ischemia; (In electrocardiography, the ST segment connects the QRS complex and the T wave and has a duration of 0.080 to 0.120 sec (80 to 120 ms).~* a positive test of a biomarker, indicating myocardial necrosis; or one of several risk factors;~* age \>60 years~* previous myocardial infarction or Coronary-Artery Bypass Grafting \[CABG\];~* coronary artery disease with stenosis of ≥50% in at least two vessels;~* previous ischemic stroke, transient ischemic attack, carotid stenosis of at least 50%, or cerebral revascularization;~* diabetes mellitus;~* peripheral arterial disease;~* or chronic renal dysfunction, defined as a creatinine clearance of \<60 ml per minute per 1.73 m2 of body surface area).~* patients with symptoms of unstable angina lasting ≥10 min and either an elevated troponin I level or newly developed ST-segment depression of 1 mm or transient ST-segment elevation of 1 mm will also be included.~Exclusion Criteria:~Subjects should not enter the study if any of the following exclusion criteria are fulfilled:~* Patients with active pathological bleeding or a history of intracranial bleeding;~* patients with planned to urgent coronary artery bypass graft surgery;~* severe hepatic impairment;~* concomitant therapy with a strong cytochrome P-450 3A inhibitors, where 3A is s subfamily of the cytochrome P450 superfamily of genes;~* surgery\<4 weeks;~* the use of any thienopyridine (within the previous two weeks);~* upstream use of Glycoprotein (GP) IIb/IIIa inhibitors;~* bleeding diathesis or major bleeding episode within 2 weeks;~* a need for oral anticoagulation therapy;~* thrombocytopenia;~* presence of thrombus in the coronary artery; incessant chest pain or hemodynamic instability;~* and patients with glomerular filtration rate (GFR)\<30 mL/min or on hemodialysis.~* maintenance dose of aspirin above 100mg~* history of allergies to Ticagrelor~* patients at increased risk of bradycardic events (e.g., patients who have sick sinus syndrome, 2nd or 3rd degree Atrioventricular block (AV block), or bradycardic related syncope and not protected with a pacemaker~* women who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ticagrelor and Eptifibatide bolus (Type: ACTIVE_COMPARATOR): Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
- Ticagrelor & Eptifibatide bolus+infusion (Type: ACTIVE_COMPARATOR): Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)

Based on this trial design, predict the completion outcome and termination type (if applicable).